Sellas Life Sciences
SLS
11.31
-0.03
-0.26%
Sellas Life Sciences
US · SLS
#2687 by market cap
Listed 1970
11.31
-0.03
-0.26%
Live - 5344 symbols - heartbeat 49s ago
· 2026-10-08 07:00
Pre-market
11.31
0.00%
After-hours
11.35
+0.35%
Overnight
11.32
+0.09%
- Market cap
- 2.28B
- P/E (TTM)i
- -51.41
- P/Bi
- 16.58
- EPSi
- -0.25
- Div yieldi
- 0.00%
- 52W posi
- 68%
Reader sentiment
Are you bullish or bearish on SLS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 5 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.6 percentage points.
Institutional ownership
- Held by institutions
- 36.69% -0.57pp
- Institutions
- 222 +5
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund29.67%
Hedge Fund2.66%
Private Company2.15%
Public Company1.71%
Individual/Insider0.39%
Government Pension Fund0.29%
Family Office/Trust0.20%
Other62.91%
Top holders as of 2026-06-30
BlackRock
7.46% · 15.07M sh
State Street Global Advisors
6.44% · 13.00M sh
Vanguard Capital Management, LLC
4.73% · 9.56M sh
Geode Capital Management, LLC
2.42% · 4.88M sh
Anson Group
2.23% · 4.50M sh
Edward Jones Trust Company
1.14% · 2.30M sh
Vanguard Portfolio Management, LLC
1.07% · 2.16M sh
Susquehanna International Group, LLP
1.02% · 2.05M sh
Northern Trust Global Investments
0.80% · 1.62M sh
UBS Asset Management
0.76% · 1.53M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 41 buys · 6 sells
| Name | Role | Stake |
|---|---|---|
| Angelos Stergiou | Chief Executive Officer | 0.15% |
| John Burns | Senior Vice President | 0.07% |
| Dragan Cicic | Senior Vice President of Clinical Development | 0.06% |
| Katherine Kalin | Independent Director | 0.05% |
| Jane Wasman | Independent Chairperson | 0.02% |
| Robert Van Nostrand | Independent Director | 0.02% |
| David Scheinberg | Independent Director | 0.01% |
| John Varian | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-15 | Angelos Stergiou | Chief Executive Officer | Other Acquisition | +1,065,000 | -- |
| 2026-01-06 | Robert Van Nostrand | Independent Director | Other Acquisition | +50,000 | -- |
| 2026-01-06 | John Varian | Independent Director | Other Acquisition | +50,000 | -- |
| 2026-01-06 | David Scheinberg | Independent Director | Other Acquisition | +50,000 | -- |
| 2026-01-06 | Jane Wasman | Independent Chairperson | Other Acquisition | +50,000 | -- |
| 2026-01-06 | Dragan Cicic | Senior Vice President of Clinical Development | Other Acquisition | +300,000 | -- |
| 2026-01-06 | John Burns | Senior Vice President | Other Acquisition | +300,000 | -- |
| 2026-01-06 | Katherine Kalin | Independent Director | Other Acquisition | +50,000 | -- |
| 2025-12-02 | Dragan Cicic | Senior Vice President of Clinical Development | Other Disposition | -63,800 | $1.50 |
| 2025-12-02 | Angelos Stergiou | Chief Executive Officer | Other Disposition | -187,066 | $1.50 |
| 2025-12-02 | John Burns | Senior Vice President | Other Disposition | -58,592 | $1.50 |
| 2025-11-18 | Katherine Kalin | Independent Director | Open Market Acquisition | +63,400 | $1.59 |
| 2025-06-11 | Robert Van Nostrand | Independent Director | Open Market Acquisition | +10,000 | $1.48 |
| 2025-05-29 | Jane Wasman | Independent Chairperson | Open Market Acquisition | +20,000 | $1.69 |
| 2025-05-21 | Katherine Kalin | Independent Director | Open Market Acquisition | +20,000 | $1.80 |
| 2025-01-09 | Robert Van Nostrand | Independent Director | Other Acquisition | +12,500 | -- |
| 2025-01-09 | Robert Van Nostrand | Independent Director | Other Derivative Acquisition | +18,500 | $0.95 |
| 2025-01-09 | John Varian | Independent Director | Other Acquisition | +12,500 | -- |
| 2025-01-09 | John Varian | Independent Director | Other Derivative Acquisition | +18,500 | $0.95 |
| 2025-01-09 | David Scheinberg | Independent Director | Other Acquisition | +12,500 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:00:00 · For reference only, not investment advice and not tailored to your situation.